Literature DB >> 33536516

Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women.

Manako Yamaguchi1, Masayuki Sekine2, Sharon J B Hanley3, Risa Kudo1, Megumi Hara4, Sosuke Adachi1, Yutaka Ueda5, Etsuko Miyagi6, Takayuki Enomoto1.   

Abstract

In Japan, recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears. Although vaccine opponents claim modifying sexual behavior can prevent cervical cancer, no comprehensive data exist on sexual behavior and the risk of high-grade cervical disease in a Japanese population. This study investigates sexual behavior and the risk of HPV infection and cervical disease in 3968 women aged 20-41 yrs undergoing cervical screening between April 2014 and March 2016. Mean age at first intercourse was 18.4 yrs ± 2.8 and 32% of women reported ≥ 6 lifetime sexual partners. In regression analyses, number of partners was a significant risk factor for HPV infection. However, for high-grade disease (CIN2+), when HPV genotype was adjusted for, number of partners was not statistically significant. The greatest risk factor was an HPV16/18 infection (adjusted odds ratio 113.7, 95% CI: 40.8-316.9). In conclusion, we found that having an HPV16/18 infection and not sexual behavior was the most significant risk factor for high grade cervical disease in young Japanese women. These infections can be prevented by a highly effective vaccine and we recommend that the Japanese government resume proactive recommendations for the HPV vaccine immediately.

Entities:  

Year:  2021        PMID: 33536516     DOI: 10.1038/s41598-021-82354-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  25 in total

Review 1.  Challenges in breast and cervical cancer control in Japan.

Authors:  Catherine Sauvaget; Yoshikazu Nishino; Ryo Konno; Toru Tase; Tadaoki Morimoto; Shigeru Hisamichi
Journal:  Lancet Oncol       Date:  2016-07       Impact factor: 41.316

2.  Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: an analysis using the Kanagawa population-based Cancer Registry, 1975-2012.

Authors:  Yoko Motoki; Shunsaku Mizushima; Masataka Taguri; Kenzo Takahashi; Ryoko Asano; Hisamori Kato; Mikiko Asai-Sato; Kayoko Katayama; Naoyuki Okamoto; Fumiki Hirahara; Etsuko Miyagi
Journal:  Cancer Epidemiol       Date:  2015-08-12       Impact factor: 2.984

3.  Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance.

Authors:  C E Schmeink; L F A G Massuger; C H Lenselink; W G V Quint; B I Witte; J Berkhof; W J G Melchers; R L M Bekkers
Journal:  Int J Cancer       Date:  2013-03-07       Impact factor: 7.396

Review 4.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

5.  Incidence, clearance and predictors of human papillomavirus infection in women.

Authors:  John W Sellors; Tina L Karwalajtys; Janusz Kaczorowski; James B Mahony; Alice Lytwyn; Sylvia Chong; Joanna Sparrow; Attila Lorincz
Journal:  CMAJ       Date:  2003-02-18       Impact factor: 8.262

6.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Authors:  Michelle J Khan; Philip E Castle; Attila T Lorincz; Sholom Wacholder; Mark Sherman; David R Scott; Brenda B Rush; Andrew G Glass; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

Review 7.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

8.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Authors:  Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

9.  Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain.

Authors:  F X Bosch; X Castellsagué; N Muñoz; S de Sanjosé; A M Ghaffari; L C González; M Gili; I Izarzugaza; P Viladiu; C Navarro; A Vergara; N Ascunce; E Guerrero; K V Shah
Journal:  J Natl Cancer Inst       Date:  1996-08-07       Impact factor: 13.506

Review 10.  Chapter 6: Immunosuppression and co-infection with HIV.

Authors:  Joel M Palefsky; Elizabeth A Holly
Journal:  J Natl Cancer Inst Monogr       Date:  2003
View more
  3 in total

1.  Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.

Authors:  Risa Kudo; Masayuki Sekine; Manako Yamaguchi; Megumi Hara; Sharon J B Hanley; Megumi Kurosawa; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Sayaka Ikeda; Asami Yagi; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2022-07-11       Impact factor: 6.518

2.  Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.

Authors:  Mamiko Onuki; Kasumi Yamamoto; Hideaki Yahata; Hiroyuki Kanao; Harushige Yokota; Hisamori Kato; Kumi Shimamoto; Kazuhiro Takehara; Shoji Kamiura; Naotake Tsuda; Yuji Takei; Shogo Shigeta; Noriomi Matsumura; Hiroyuki Yoshida; Takeshi Motohara; Hidemichi Watari; Keiichiro Nakamura; Akihiko Ueda; Nobutaka Tasaka; Mitsuya Ishikawa; Yasuyuki Hirashima; Wataru Kudaka; Ayumi Taguchi; Takashi Iwata; Fumiaki Takahashi; Iwao Kukimoto; Hiroyuki Yoshikawa; Nobuo Yaegashi; Koji Matsumoto
Journal:  Cancer Sci       Date:  2022-02-02       Impact factor: 6.716

3.  Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.

Authors:  Megumi Kurosawa; Masayuki Sekine; Manako Yamaguchi; Risa Kudo; Sharon J B Hanley; Megumi Hara; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Sayaka Ikeda; Asami Yagi; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2022-02-14       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.